DUBLIN, OH - January 5, 2012 -- Neoprobe Corporation (NEOP)
today announced that it has completed its corporate name
change to Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB).
The Company will begin trading under the ticker symbol, NAVB,
on the NYSE Amex at market open today. The CUSIP number for
NAVB common stock has also been changed to
63937X103.
The Navidea name and logo represent the Company's dedication
to "NAVigating IDEAs" that translate cutting edge innovation
and precision diagnostics technology into novel products to
advance patient care.
Navidea's website is expected to be launched in the coming
days and may be found at www.navidea.com.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals (NYSE Amex: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms - Lymphoseek®, AZD4694 and RIGScanTM - to help identify the presence and status of disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Contacts:
Navidea Biopharmaceuticals -- Brent Larson, Sr. VP & CFO - (614) 822-2330
distribué par | Ce noodl a été diffusé par Navidea Biopharmaceuticals Inc. et initialement mise en ligne sur le site http://www.navidea.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-05 23:30:39 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |
Documents associés | |
Neoprobe Corporation Becomes Navidea Biopharmaceuticals |